Cargando…
Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem
Long non-coding RNAs (lncRNAs) are an emerging group of RNAs with a crucial role in cancer pathogenesis. In gastrointestinal cancers, TP53 target 1 (TP53TG1) is an epigenetically regulated lncRNA that represents a promising therapeutic target due to its tumor suppressor properties regulating the p53...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470159/ https://www.ncbi.nlm.nih.gov/pubmed/34575588 http://dx.doi.org/10.3390/pharmaceutics13091507 |
_version_ | 1784574127202369536 |
---|---|
author | Masoumi, Farimah Saraiva, Sofia M. Bouzo, Belén L. López-López, Rafael Esteller, Manel Díaz-Lagares, Ángel de la Fuente, María |
author_facet | Masoumi, Farimah Saraiva, Sofia M. Bouzo, Belén L. López-López, Rafael Esteller, Manel Díaz-Lagares, Ángel de la Fuente, María |
author_sort | Masoumi, Farimah |
collection | PubMed |
description | Long non-coding RNAs (lncRNAs) are an emerging group of RNAs with a crucial role in cancer pathogenesis. In gastrointestinal cancers, TP53 target 1 (TP53TG1) is an epigenetically regulated lncRNA that represents a promising therapeutic target due to its tumor suppressor properties regulating the p53-mediated DNA damage and the intracellular localization of the oncogenic YBX1 protein. However, to translate this finding into the clinic as a gene therapy, it is important to develop effective carriers able to deliver exogenous lncRNAs to the targeted cancer cells. Here, we propose the use of biocompatible sphingomyelin nanosystems comprising DOTAP (DSNs) to carry and deliver a plasmid vector encoding for TP53TG1 (pc(TP53TG1)-DSNs) to a colorectal cancer cell line (HCT-116). DSNs presented a high association capacity and convenient physicochemical properties. In addition, pc(TP53TG1)-DSNs showed anti-tumor activities in vitro, specifically a decrease in the proliferation rate, a diminished colony-forming capacity, and hampered migration and invasiveness of the treated cancer cells. Consequently, the proposed strategy displays a high potential as a therapeutic approach for colorectal cancer. |
format | Online Article Text |
id | pubmed-8470159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84701592021-09-27 Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem Masoumi, Farimah Saraiva, Sofia M. Bouzo, Belén L. López-López, Rafael Esteller, Manel Díaz-Lagares, Ángel de la Fuente, María Pharmaceutics Article Long non-coding RNAs (lncRNAs) are an emerging group of RNAs with a crucial role in cancer pathogenesis. In gastrointestinal cancers, TP53 target 1 (TP53TG1) is an epigenetically regulated lncRNA that represents a promising therapeutic target due to its tumor suppressor properties regulating the p53-mediated DNA damage and the intracellular localization of the oncogenic YBX1 protein. However, to translate this finding into the clinic as a gene therapy, it is important to develop effective carriers able to deliver exogenous lncRNAs to the targeted cancer cells. Here, we propose the use of biocompatible sphingomyelin nanosystems comprising DOTAP (DSNs) to carry and deliver a plasmid vector encoding for TP53TG1 (pc(TP53TG1)-DSNs) to a colorectal cancer cell line (HCT-116). DSNs presented a high association capacity and convenient physicochemical properties. In addition, pc(TP53TG1)-DSNs showed anti-tumor activities in vitro, specifically a decrease in the proliferation rate, a diminished colony-forming capacity, and hampered migration and invasiveness of the treated cancer cells. Consequently, the proposed strategy displays a high potential as a therapeutic approach for colorectal cancer. MDPI 2021-09-18 /pmc/articles/PMC8470159/ /pubmed/34575588 http://dx.doi.org/10.3390/pharmaceutics13091507 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Masoumi, Farimah Saraiva, Sofia M. Bouzo, Belén L. López-López, Rafael Esteller, Manel Díaz-Lagares, Ángel de la Fuente, María Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem |
title | Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem |
title_full | Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem |
title_fullStr | Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem |
title_full_unstemmed | Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem |
title_short | Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem |
title_sort | modulation of colorectal tumor behavior via lncrna tp53tg1-lipidic nanosystem |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470159/ https://www.ncbi.nlm.nih.gov/pubmed/34575588 http://dx.doi.org/10.3390/pharmaceutics13091507 |
work_keys_str_mv | AT masoumifarimah modulationofcolorectaltumorbehaviorvialncrnatp53tg1lipidicnanosystem AT saraivasofiam modulationofcolorectaltumorbehaviorvialncrnatp53tg1lipidicnanosystem AT bouzobelenl modulationofcolorectaltumorbehaviorvialncrnatp53tg1lipidicnanosystem AT lopezlopezrafael modulationofcolorectaltumorbehaviorvialncrnatp53tg1lipidicnanosystem AT estellermanel modulationofcolorectaltumorbehaviorvialncrnatp53tg1lipidicnanosystem AT diazlagaresangel modulationofcolorectaltumorbehaviorvialncrnatp53tg1lipidicnanosystem AT delafuentemaria modulationofcolorectaltumorbehaviorvialncrnatp53tg1lipidicnanosystem |